March 21, 2019
Verona Pharma welcomes Non-Executive Director
Verona Pharma as Non-Executive Director
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
March 21, 2019
New Oasmia board to review business, searching intense dialogue with the stock market and shareholders
The new Oasmia board, led by Jörgen Olsson who was elected as the Chairman, independent Board member and former CEO of Hoist Finance, will review the business and proceedings of Oasmia in several aspects.
March 20, 2019
Merck, Pfizer dropping program from Phase III Javelin Ovarian PARP study
German Merck, which operates its biopharmaceutical business as EMD Serono in the US and Canada, and Pfizer are dropping the Phase III JAVELIN Ovarian PARP 100 study in which they tested avelumab combined with chemotherapy followed by maintenance therapy of avelumab in combination with talazoparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, versus an active comparator in treatment-naïve patients with locally advanced or metastatic ovarian cancer (Stage III or Stage IV), as they described in the press release on Wednesday.
March 20, 2019
Sage Therapeutics gets approval for Zulresso, first new drug to treat postpartum depression
Sage Therapeutics got clearance from the FDA has approved Zulresso (brexanolone) injection for the treatment of postpartum depression (PPD), and is the first and only medicine specifically approved to treat PPD, the most common medical complication of childbirth.
March 20, 2019
Nordic Group, Primex Pharmaceuticals in partnership to sell Ozalin in France
Nordic Group and Primex Pharmaceuticals AG, an innovative global Anaesthesia pharmaceutical company have partnered up to make Ozalin available in France.
March 19, 2019
AbbVie puts multiple myeloma investigational treatmenttrial on hold after higher proportion of deaths was observed in the venetoclax
AbbVie has put on hold clinical testing venetoclax (Venclexta/Venclyxto) for the investigational treatment of multiple myeloma, which being developed by AbbVie and Roche, and jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S.
March 19, 2019
Novartis’ eye care division Alcon buys US-based private mdical device company for $285M
Novartis’ eye care division Alcon has bought a privately-held US medical device company PowerVision, which focuses on focused on creating fluid-based intraocular lens implants, for $285 million at closing with additional payments based on specified regulatory and commercial milestones starting in 2023.
March 19, 2019
Amarin Corporation’s Vascepa significantly reduces total cardiovascular events in REDUCE-IT study
Amarin Corporation’s Vascepa provided a statistically significant 30% risk reduction in total (first and subsequent) cardiovascular events compared to placebo in the statin-treated patient population studied in REDUCE-IT, as presented in a cardiovascular outcomes study.
March 19, 2019
Allergan expands label for Avycaz, for intra-abdominal infections
Allergan has expanded the label of Avycaz, as it got approval from the US FDA for its supplemental New Drug Application (sNDA), for treating young patients with complicated intra-abdominal infections.
March 19, 2019
Pharmapack success points to sizeable growth potential for global drug delivery and packaging in 2019
The drug delivery and healthcare packaging industry is set for significant growth in 2019 as Pharmapack Europe – a key bellwether of industry health – welcomed a record 410 exhibiting companies and nearly 5,500 attendees from 75 countries. Europe’s biggest pharmaceutical packaging and drug delivery event (Paris Expo, Porte de Versailles, France 6-7 February, 2019) saw a diversification of innovations and new drug delivery solutions, with ‘patient-centricity’ emerging as the central theme throughout this year’s edition.